

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Bio-heart Biological Technology Co., Ltd.**

### **上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

### **VOLUNTARY ANNOUNCEMENT COMPLETION OF THE CONSTRUCTION AND THE OPERATION OF THE NEW PLANT**

#### **COMPLETION OF THE CONSTRUCTION AND THE OPERATION OF THE NEW PLANT**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

Reference is made to the Company’s prospectus published on December 13, 2021 (the “**Prospectus**”). Unless otherwise specified, capitalised terms used herein shall have the same meanings as defined in the Prospectus.

The board of directors of the Company (the “**Board**”) is pleased to announce that the construction of the Company’s new plant (the “**Plant**”) located at Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai with a gross area of over 7,000 sq.m was completed on December 31, 2021, of which, the production site located at the second and third floor with a total gross area of 3,600 sq.m (including a class 10,000 cleanroom production area with a gross area of over 2,000 sq.m) has passed the relevant inspections, completed the relevant filings and has been officially put into use.

As disclosed in the section headed “Business – Our Production Facilities and Processes” in the Prospectus, the completion of the construction of the Plant is beneficial to the growth of our business scale and production capacity, improves efficiency, and enables us to impose stricter quality control over the products. At the early design stage of the Plant, our need for standardized mass production has been considered, and the Plant is equipped with infrastructures such as leading purifying air-conditioning system, process air system and process water system in the industry. A number of class 100 cleanroom production sites in compliance with the Good Manufacturing Practice (GMP) have been built, so as to ensure the stability and high output of certain critical/special working procedures. The supporting production and inspection equipment inside the Plant are either originated from the benchmark product of internationally renowned manufacturers or self-designed by our technicians who own all intellectual property rights and patents. They fit our product characteristics as well as our production and inspection requirements, thus laying a solid foundation for the continuous increase of product capacity and quality improvement of the products. It is expected that through the addition of production lines, recruitment and training of technicians in the future, the Plant can achieve the production capacity goal of 280,000 units of bioresorbable scaffolds (BRS) products and 90,000 units of renal denervation (RDN) products per year.

At the same time, the completion of the Plant is beneficial for the consolidation of our internal advantageous resources and establishment of an innovative technology platform comprising various product portfolios. We will leverage on the advantages of this platform to construct innovation centers for our future products, so as to meet the evolving clinical needs of the physicians and patients. Going forward, with the operation of the Plant, we will possess all-round solution capabilities in terms of research and development, production, inspection, registration, product marketing and brand management of medical devices, which will bring good news to more patients in the fields of coronary and peripheral artery disease as well as those with hypertension.

The Board wishes to note that no forecast or prediction of the profits of the Group has been made in relation to the completion of the construction of the Plant and/or its expected commencement of production.

**Shareholders and potential investors are therefore advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman and executive director*

Shanghai, the People’s Republic of China, January 9, 2022

*As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.*